Term ends no later than May 5, 2030 · Medium confidence
20-year base term ends Sep 22, 2029
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Phio Pharmaceuticals Corp.
Filed Oct 7, 2011 as application 13/120,342 · Granted Aug 5, 2014
Base term plus 225 days of patent term adjustment (USPTO delay)
Today
2009
2030
Clock starts
Sep 22, 2009
Sep 22, 2009
Ends no later than
May 5, 2030
May 5, 2030
Granted
Aug 5, 2014
Aug 5, 2014
base term
patent term adjustment
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
225
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 225 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 22, 2009, when application PCT/US2009/005247, the earliest non-provisional in its chain, was filed (this one was filed Oct 7, 2011) | Sep 22, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +225 days, USPTO patent term adjustment record | May 5, 2030 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than May 5, 2030 | Medium confidence |
This family
| Application PCT/US2009/005247 | PCT application no patent term | no patent term |
| US 10,041,073 | Lapsed on the fee record Aug 2026 | Aug 2026 |
| US 8,796,443 | this patent no later than May 2030 | no later than May 2030 |
| US 9,175,289 | In force no later than Sep 2029 | no later than Sep 2029 |
| US 10,774,330 | In force no later than Sep 2029 | no later than Sep 2029 |
| US 10,876,119 | Lapsed on the fee record Dec 2024 | Dec 2024 |
| Application 16/934,864 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 26, 2011 Reel 26969, frame 660 | Rxi Pharmaceuticals Corporation | RNCS, Inc. | Assignment of Assignor's Interest |
| Sep 26, 2011 Reel 26976, frame 187 | RNCS, Inc. | Tang Capital Partners, LP | Security Agreement |
| Sep 29, 2011 Reel 26988, frame 874 | RNCS, Inc. | Rxi Pharmaceuticals Corporation | Change of Name |
| May 2, 2012 Reel 28144, frame 110 | Tang Capital Partners, LP | Rxi Pharmaceuticals Corporation | Release of Security Interest |
| Jan 11, 2013 Reel 29613, frame 306 | Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Cardia, James | Rxi Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Dec 7, 2018 Reel 48380, frame 9 | Rxi Pharmaceuticals Corporation | Phio Pharmaceuticals Corp. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
May 2030
Term ends no later than May 5, 2030. No further fees fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 225 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than May 5, 2030. We will not guess the cap.
Citations
139
later US patents cite this one
That is top 5% of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.